Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor kB ligand (RANKL)

Histopathology

Volumn 59, Issue 3, 2011, Pages 397-406

  Vishvanath, Anasuya ^a,b   Itinteang, Tinte ^a,b,c   Tan, Swee T ^a,b,c,d   Day, Darren J ^a,b,c  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b HUTT HOSPITAL   (New Zealand)

^c GILLIES MCINDOE RESEARCH INSTITUTE   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Infantile haemangioma; Involution; Osteoprotegerin; RANK; RANKL; TRAIL; TRAIL receptors

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CAPILLARY ENDOTHELIUM; CAPILLARY HEMANGIOMA; CAPILLARY PROLIFERATION; CELL MATURATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CELL; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; HEMANGIOMA, CAPILLARY; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; NEOPLASTIC SYNDROMES, HEREDITARY; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80053335094     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03970.x     Document Type: Article

References (32)

1. Cross SS, Yang Z, Brown NJ et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int. J. Cancer 2006; 118; 1901-1908.
2. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002; 62; 1619-1623.
3. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur. J. Cell Biol. 2009; 88; 1-17.
4. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12; 611-620.
5. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumour necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003; 63; 912-916.
6. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204; 321-329.
7. Zannettino A, Holding C, Diamond P et al. Osteoprotegerin (OPG) is localised to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J. Cell. Physiol. 2005; 204; 714-723.
8. Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast. Reconstr. Surg. 2000; 106; 529-537.
9. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J. Plast. Reconstr. Aesthet. Surg. 2010; 64; 292-299.
10. Itinteang T, Tan ST, Brasch H, Day DJ. Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J. Clin. Pathol. 2010; 63; 771-776.
11. Tan ST, Wallis RA, He Y, Davis PF. Mast cells and hemangioma. Plast. Reconstr. Surg. 2004; 113; 999-1011.
12. Tan ST, Hasan Q, Velickovic M, Ruger BM, Davis RPF, Davis PF. A novel in vitro human model of hemangioma. Mod. Pathol. 2000; 13; 92-99.
13. Pinheiro JC, Bates DM. Statistics and computing series. NY: Springer-Verlag, 2000.
14. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumour cell biology. Cell. Mol. Life Sci. 2009; 66; 841-851.
15. Itinteang T, Tan ST, Brasch H, Day DJ. Haemogenic endothelium in infantile haemangioma. J. Clin. Pathol. 2010; 63; 982-986.
16. Hatzopoulos AK, Folkman J, Vasile E, Eiselen GK, Rosenberg RD. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development 1998; 125; 1457-1468.
17. Reid P, Brown N, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol. Cancer 2009; 8; 49.
18. Kobayashi-Sakamoto M, Isogai E, Holen I. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signalling in endothelial cells. Eur. J. Haematol. 2010; 85; 26-35.
19. Baud'huin M, Duplomb L, Teletchea S et al. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J. Biol. Chem. 2009; 284; 31704-31713.
20. Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S. Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br. J. Haematol. 2010; 148; 805-807.
21. Fili S, Karalaki M, Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int. 2009; 9; 26.
22. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc. Natl Acad. Sci. USA 2002; 99; 7455-7460.
23. Atkins GJ, Bouralexis S, Haynes DR et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumours of bone. Bone 2001; 28; 370-377.
24. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumour necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 2004; 15; 2834-2841.
25. Miyashita T, Kawakami A, Nakashima T et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin. Exp. Immunol. 2004; 137; 430-436.
26. Neville-Webbe HL, Cross NA, Eaton CL et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from trail-induced apoptosis. Breast Cancer Res. Treat. 2004; 86; 271-282.
27. Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006; 42; 415-420.
28. Kanzaki H, Chiba M, Sato A et al. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. J. Dent. Res. 2006; 85; 457-462.
29. Yamamoto Y, Udagawa N, Matsuura S et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-{kappa}B ligand. Endocrinology 2006; 147; 3366-3374.
30. Tang L, Lin Z, Li Y-M. Effects of different magnitudes of mechanical strain on osteoblasts in vitro. Biochem. Biophys. Res. Commun. 2006; 344; 122-128.
31. 3 in abdominal aortic aneurysm. J. Vasc. Res. 2009; 46; 209-217.
32. Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J. Plast. Reconstr. Aesthet. Surg. 2011; 64; 759-765.